1-MNA

Supplement

1-MNA, a novel myokine, is a game-changer in cellular, vascular, and lipid health by blocking the enzyme NNMT and optimizing NAD levels in the cells.

Services
  • Safely Supports NAD Levels
  • Reduces Inflammatory Proteins
  • Supports Healthy Blood Vessels
Location Boulder, Colorado
About

1-MNA

1-MNA or ‘1-methylnicotinamide’ is a unique supplement that helps block the enzyme NNMT, supporting metabolic, brain, and cellular health by optimizing NAD levels.

1-MNA has been shown to inhibit the enzyme NNMT, which when present in high levels, is associated with various diseases. By inhibiting this enzyme, 1-MNA can contribute to overall cellular health and disease prevention.

Researched extensively for its safety profile, 1-MNA supplementation aims to safely restore NAD levels, optimize cellular redox pathways, and combat age-related diseases comprehensively. As a natural byproduct of vitamin B3, 1-MNA also shows anti-inflammatory effects and supports vascular and cardiovascular health, making it a strong candidate for daily use.

* Safely increase NAD levels and block NNMT
* Renowned for its anti-inflammatory and anti-thrombotic qualities
* Improve cell energy metabolism
* Positive effect on Vascular Endothelium
* Lowers levels of inflammatory markers

1-MNA is the flagship supplement of Longevity Launch Labs—affectionately known as Launch. Launch is a dynamic incubator dedicated to fostering groundbreaking products, services, and technologies that address the most pressing challenges in Cellular and Longevity Medicine.

At Launch, we bring years of industry expertise and a deep understanding of the business of medicine to empower founders as they navigate the complexities of today’s healthcare landscape. Our mission is to push the boundaries of innovation and transform the future of healthcare.

Join us in shaping a healthier, longer tomorrow—together.

Unlock exclusive discounts and offers from 1-MNA and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

I strongly recommend 1-MNA because it delivers the energy, vascular, and lipid benefits patients are looking for—without the uncertainties that come with NAD precursors. In my clinic, we’ve seen patients experience noticeable improvements in energy and significant gains in lipid profiles, including reductions in Lp(a). Unlike other NAD supplements, which may carry long-term risks, 1-MNA offers a safer, more targeted way to support healthy aging and cellular resilience.

Elizabeth Yurth, MD, ABPMR, ABAARM, FAARM, FAARFM, FSSRP - Co-Founder & Chief Medical Officer - Boulder Longevity Institute Boulder Longevity Institute

Unlike other NAD boosting supplements, 1-MNA is a safe and effective way to restore NAD levels and combat age related diseases, while in addition, improving vascular health, reducing inflammation, having anti-oxidant and neuroprotective properties and improving athletic recovery. I think of it as a kind of “supplement superhero” with a litany of longevity-supporting effects.

Dr. Frank Lipman Founder - Eleven Eleven Wellness Center
Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Grand Rounds
December 4 - 5, 2026

Grand Rounds

Coming Soon
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Sep 15, 2026
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman

Dr. Seeds sits down with Omar Rahman, M.D. to talk about how peptide therapy can enhance orthopedic outcomes and speed up healing in patients.

Peptides & Protocols · Performance & Recovery
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
VIDEO
Cellular Medicine Mondays
Sep 14, 2026
Ep. 105 - Dr. Seeds’ Office Hours
Preview Only
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE [August 21, 2026] – JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the […]
READ NEWS
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE